Biofrontera AG

XTRA:B8FK Stock Report

Market Cap: €13.5m

Biofrontera Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biofrontera.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Oct 13
Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

May 21
Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07
Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07
Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08
Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14
Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biofrontera has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

XTRA:B8FK - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024180N/AN/AN/A
6/30/202422-3-5-4N/A
3/31/2024300N/AN/AN/A
12/31/2023320-3-2N/A
9/30/202329-9N/AN/AN/A
6/30/202328-11-4-3N/A
3/31/202325-20N/AN/AN/A
12/31/202226-44-5-4N/A
9/30/20223211N/AN/AN/A
6/30/202231103333N/A
3/31/20223015N/AN/AN/A
12/31/202129383030N/A
9/30/202128-16N/AN/AN/A
6/30/202127-16-8-7N/A
3/31/202129-12N/AN/AN/A
12/31/202030-13-4-3N/A
9/30/202033-17N/AN/AN/A
6/30/202033-22-14-12N/A
3/31/202031-10N/AN/AN/A
12/31/201931-7-35-33N/A
9/30/2019261N/AN/AN/A
6/30/2019268-29-28N/A
3/31/201923-8N/AN/AN/A
12/31/201821-9-14-13N/A
9/30/201819-14-13-13N/A
6/30/201816-15N/A-12N/A
3/31/201814-16N/AN/AN/A
12/31/201712-16N/A-13N/A
9/30/201711-18N/A-16N/A
6/30/20179-16N/A-16N/A
3/31/20178-14N/A-15N/A
12/31/20166-11N/A-10N/A
9/30/20164-9N/A-8N/A
6/30/20164-7N/A-6N/A
3/31/20164-9N/A-8N/A
12/31/20154-11N/A-10N/A
9/30/20154-12N/A-10N/A
6/30/20153-13N/A-10N/A
3/31/20153-10N/A-7N/A
12/31/20143-11N/A-8N/A
9/30/20143-10N/A-8N/A
6/30/20143-10N/A-7N/A
3/31/20143-9N/A-7N/A
12/31/20133-8N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if B8FK's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if B8FK's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if B8FK's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if B8FK's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if B8FK's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if B8FK's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 21:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biofrontera AG is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Navid MalikCavendish Historical (Cenkos Securities)
Robert WassermanDawson James Securities